nodes	percent_of_prediction	percent_of_DWPC	metapath
Tiagabine—SLC6A1—NRF2 pathway—ALDH3A1—esophageal cancer	0.017	0.0576	CbGpPWpGaD
Tiagabine—SLC6A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.0159	0.0539	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—BLVRB—esophageal cancer	0.0152	0.0513	CbGpPWpGaD
Tiagabine—SLC6A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.0146	0.0493	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—PRDX1—esophageal cancer	0.0129	0.0436	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—SLC39A6—esophageal cancer	0.0115	0.0389	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—ADH7—esophageal cancer	0.011	0.0371	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—ABCC2—esophageal cancer	0.00796	0.027	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—NFE2L2—esophageal cancer	0.0074	0.0251	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00724	0.0245	CbGpPWpGaD
Tiagabine—CYP3A4—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.00679	0.023	CbGpPWpGaD
Tiagabine—SLC6A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00662	0.0224	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—CYP2A6—esophageal cancer	0.00636	0.0216	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00561	0.019	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—ADH7—esophageal cancer	0.00537	0.0182	CbGpPWpGaD
Tiagabine—SLC6A1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00526	0.0178	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—ALDH3A2—esophageal cancer	0.00473	0.016	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—ADH1B—esophageal cancer	0.00471	0.016	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—TGFBR2—esophageal cancer	0.00446	0.0151	CbGpPWpGaD
Tiagabine—SLC6A1—NRF2 pathway—HMOX1—esophageal cancer	0.0044	0.0149	CbGpPWpGaD
Tiagabine—CYP3A4—Irinotecan Pathway—ABCC2—esophageal cancer	0.00434	0.0147	CbGpPWpGaD
Tiagabine—SLC6A1—Neuronal System—GNG7—esophageal cancer	0.0043	0.0146	CbGpPWpGaD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.00417	0.0141	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00413	0.014	CbGpPWpGaD
Tiagabine—SLC6A1—Neuronal System—ALDH2—esophageal cancer	0.00403	0.0137	CbGpPWpGaD
Tiagabine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—esophageal cancer	0.00398	0.0135	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00388	0.0131	CbGpPWpGaD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.00372	0.0126	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00368	0.0125	CbGpPWpGaD
Tiagabine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.00361	0.0122	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00351	0.0119	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00336	0.0114	CbGpPWpGaD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00336	0.0114	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—ALDH2—esophageal cancer	0.00332	0.0112	CbGpPWpGaD
Tiagabine—CYP3A4—Fatty Acid Omega Oxidation—CYP2A6—esophageal cancer	0.00312	0.0106	CbGpPWpGaD
Tiagabine—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00291	0.00414	CcSEcCtD
Tiagabine—Hypokalaemia—Cisplatin—esophageal cancer	0.0029	0.00412	CcSEcCtD
Tiagabine—Apnoea—Methotrexate—esophageal cancer	0.00285	0.00404	CcSEcCtD
Tiagabine—Abnormal vision—Capecitabine—esophageal cancer	0.00283	0.00401	CcSEcCtD
Tiagabine—Mental disability—Capecitabine—esophageal cancer	0.00281	0.00399	CcSEcCtD
Tiagabine—Sepsis—Capecitabine—esophageal cancer	0.00281	0.00399	CcSEcCtD
Tiagabine—Speech disorder—Methotrexate—esophageal cancer	0.0028	0.00398	CcSEcCtD
Tiagabine—Ear pain—Capecitabine—esophageal cancer	0.00276	0.00391	CcSEcCtD
Tiagabine—Phlebitis—Capecitabine—esophageal cancer	0.00273	0.00387	CcSEcCtD
Tiagabine—Thrombophlebitis—Capecitabine—esophageal cancer	0.00272	0.00386	CcSEcCtD
Tiagabine—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00269	0.00382	CcSEcCtD
Tiagabine—Polyuria—Capecitabine—esophageal cancer	0.00268	0.0038	CcSEcCtD
Tiagabine—Gastroenteritis—Capecitabine—esophageal cancer	0.00265	0.00377	CcSEcCtD
Tiagabine—Deafness—Capecitabine—esophageal cancer	0.00263	0.00373	CcSEcCtD
Tiagabine—Herpes simplex—Methotrexate—esophageal cancer	0.00262	0.00371	CcSEcCtD
Tiagabine—Glossitis—Methotrexate—esophageal cancer	0.00262	0.00371	CcSEcCtD
Tiagabine—CYP3A4—Xenobiotics—CYP2A6—esophageal cancer	0.00261	0.00884	CbGpPWpGaD
Tiagabine—Eye pain—Capecitabine—esophageal cancer	0.00261	0.0037	CcSEcCtD
Tiagabine—Dysarthria—Methotrexate—esophageal cancer	0.00255	0.00362	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00255	0.00863	CbGpPWpGaD
Tiagabine—Libido decreased—Capecitabine—esophageal cancer	0.00254	0.0036	CcSEcCtD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00251	0.0085	CbGpPWpGaD
Tiagabine—Increased appetite—Capecitabine—esophageal cancer	0.0025	0.00355	CcSEcCtD
Tiagabine—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.00249	0.00354	CcSEcCtD
Tiagabine—Thirst—Capecitabine—esophageal cancer	0.00247	0.00351	CcSEcCtD
Tiagabine—Dermatitis bullous—Capecitabine—esophageal cancer	0.00246	0.00349	CcSEcCtD
Tiagabine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00242	0.00344	CcSEcCtD
Tiagabine—Arthritis—Capecitabine—esophageal cancer	0.00242	0.00343	CcSEcCtD
Tiagabine—Renal failure—Cisplatin—esophageal cancer	0.00242	0.00343	CcSEcCtD
Tiagabine—Vaginal inflammation—Methotrexate—esophageal cancer	0.00241	0.00342	CcSEcCtD
Tiagabine—Myocardial infarction—Cisplatin—esophageal cancer	0.00241	0.00342	CcSEcCtD
Tiagabine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00241	0.00342	CcSEcCtD
Tiagabine—Stomatitis—Cisplatin—esophageal cancer	0.0024	0.0034	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.0024	0.00812	CbGpPWpGaD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.0024	0.00812	CbGpPWpGaD
Tiagabine—Conjunctivitis—Cisplatin—esophageal cancer	0.00239	0.00339	CcSEcCtD
Tiagabine—Hyponatraemia—Capecitabine—esophageal cancer	0.00236	0.00335	CcSEcCtD
Tiagabine—Melaena—Methotrexate—esophageal cancer	0.00236	0.00334	CcSEcCtD
Tiagabine—Cystitis noninfective—Methotrexate—esophageal cancer	0.00236	0.00334	CcSEcCtD
Tiagabine—Osteoarthritis—Capecitabine—esophageal cancer	0.00235	0.00334	CcSEcCtD
Tiagabine—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00235	0.00334	CcSEcCtD
Tiagabine—Diplopia—Capecitabine—esophageal cancer	0.00235	0.00334	CcSEcCtD
Tiagabine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00233	0.00331	CcSEcCtD
Tiagabine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.00233	0.0033	CcSEcCtD
Tiagabine—Cystitis—Methotrexate—esophageal cancer	0.00233	0.0033	CcSEcCtD
Tiagabine—Migraine—Capecitabine—esophageal cancer	0.00232	0.00329	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00231	0.00783	CbGpPWpGaD
Tiagabine—CYP3A4—Estrogen metabolism—CYP1B1—esophageal cancer	0.00229	0.00775	CbGpPWpGaD
Tiagabine—Vaginal infection—Methotrexate—esophageal cancer	0.00228	0.00323	CcSEcCtD
Tiagabine—Face oedema—Capecitabine—esophageal cancer	0.00227	0.00322	CcSEcCtD
Tiagabine—Irritability—Capecitabine—esophageal cancer	0.00225	0.00319	CcSEcCtD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00224	0.00759	CbGpPWpGaD
Tiagabine—Urinary retention—Capecitabine—esophageal cancer	0.00224	0.00317	CcSEcCtD
Tiagabine—Mood swings—Capecitabine—esophageal cancer	0.00223	0.00316	CcSEcCtD
Tiagabine—Ataxia—Capecitabine—esophageal cancer	0.00221	0.00314	CcSEcCtD
Tiagabine—Coma—Methotrexate—esophageal cancer	0.0022	0.00313	CcSEcCtD
Tiagabine—Dehydration—Capecitabine—esophageal cancer	0.00219	0.0031	CcSEcCtD
Tiagabine—Neoplasm—Methotrexate—esophageal cancer	0.00218	0.00309	CcSEcCtD
Tiagabine—Ecchymosis—Methotrexate—esophageal cancer	0.00218	0.00309	CcSEcCtD
Tiagabine—Mouth ulceration—Methotrexate—esophageal cancer	0.00218	0.00309	CcSEcCtD
Tiagabine—Bladder pain—Methotrexate—esophageal cancer	0.00218	0.00309	CcSEcCtD
Tiagabine—Urine output increased—Methotrexate—esophageal cancer	0.00218	0.00309	CcSEcCtD
Tiagabine—Liver function test abnormal—Capecitabine—esophageal cancer	0.00217	0.00308	CcSEcCtD
Tiagabine—Dry skin—Capecitabine—esophageal cancer	0.00216	0.00306	CcSEcCtD
Tiagabine—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00215	0.00305	CcSEcCtD
Tiagabine—Hypokalaemia—Capecitabine—esophageal cancer	0.00214	0.00304	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00214	0.00723	CbGpPWpGaD
Tiagabine—Visual impairment—Cisplatin—esophageal cancer	0.00213	0.00302	CcSEcCtD
Tiagabine—Sepsis—Methotrexate—esophageal cancer	0.00209	0.00297	CcSEcCtD
Tiagabine—Gastritis—Capecitabine—esophageal cancer	0.00208	0.00295	CcSEcCtD
Tiagabine—Muscular weakness—Capecitabine—esophageal cancer	0.00207	0.00294	CcSEcCtD
Tiagabine—Tinnitus—Cisplatin—esophageal cancer	0.00206	0.00292	CcSEcCtD
Tiagabine—Lymphadenopathy—Methotrexate—esophageal cancer	0.00205	0.00291	CcSEcCtD
Tiagabine—Dysphagia—Capecitabine—esophageal cancer	0.00203	0.00288	CcSEcCtD
Tiagabine—Influenza—Capecitabine—esophageal cancer	0.00203	0.00288	CcSEcCtD
Tiagabine—Asthma—Capecitabine—esophageal cancer	0.00203	0.00288	CcSEcCtD
Tiagabine—CYP3A4—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00202	0.00685	CbGpPWpGaD
Tiagabine—Thrombophlebitis—Methotrexate—esophageal cancer	0.00202	0.00287	CcSEcCtD
Tiagabine—Polyuria—Methotrexate—esophageal cancer	0.00199	0.00283	CcSEcCtD
Tiagabine—Angina pectoris—Capecitabine—esophageal cancer	0.00198	0.00281	CcSEcCtD
Tiagabine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00197	0.00668	CbGpPWpGaD
Tiagabine—Bronchitis—Capecitabine—esophageal cancer	0.00196	0.00277	CcSEcCtD
Tiagabine—Alopecia—Cisplatin—esophageal cancer	0.00195	0.00277	CcSEcCtD
Tiagabine—Dysuria—Capecitabine—esophageal cancer	0.0019	0.0027	CcSEcCtD
Tiagabine—Flatulence—Cisplatin—esophageal cancer	0.00189	0.00269	CcSEcCtD
Tiagabine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.00186	0.00263	CcSEcCtD
Tiagabine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00186	0.00263	CcSEcCtD
Tiagabine—Weight increased—Capecitabine—esophageal cancer	0.00185	0.00263	CcSEcCtD
Tiagabine—Muscle spasms—Cisplatin—esophageal cancer	0.00185	0.00262	CcSEcCtD
Tiagabine—Weight decreased—Capecitabine—esophageal cancer	0.00184	0.00261	CcSEcCtD
Tiagabine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00183	0.0026	CcSEcCtD
Tiagabine—Pneumonia—Capecitabine—esophageal cancer	0.00182	0.00259	CcSEcCtD
Tiagabine—Depression—Capecitabine—esophageal cancer	0.00181	0.00256	CcSEcCtD
Tiagabine—Tremor—Cisplatin—esophageal cancer	0.0018	0.00255	CcSEcCtD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00179	0.00607	CbGpPWpGaD
Tiagabine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00179	0.00254	CcSEcCtD
Tiagabine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00178	0.00253	CcSEcCtD
Tiagabine—Renal failure—Capecitabine—esophageal cancer	0.00178	0.00253	CcSEcCtD
Tiagabine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00178	0.00252	CcSEcCtD
Tiagabine—Myocardial infarction—Capecitabine—esophageal cancer	0.00178	0.00252	CcSEcCtD
Tiagabine—Anaemia—Cisplatin—esophageal cancer	0.00178	0.00252	CcSEcCtD
Tiagabine—Stomatitis—Capecitabine—esophageal cancer	0.00177	0.00251	CcSEcCtD
Tiagabine—Conjunctivitis—Capecitabine—esophageal cancer	0.00176	0.0025	CcSEcCtD
Tiagabine—Urinary tract infection—Capecitabine—esophageal cancer	0.00176	0.0025	CcSEcCtD
Tiagabine—Osteoarthritis—Methotrexate—esophageal cancer	0.00175	0.00248	CcSEcCtD
Tiagabine—Malaise—Cisplatin—esophageal cancer	0.00173	0.00246	CcSEcCtD
Tiagabine—Haematuria—Capecitabine—esophageal cancer	0.00173	0.00245	CcSEcCtD
Tiagabine—Leukopenia—Cisplatin—esophageal cancer	0.00172	0.00244	CcSEcCtD
Tiagabine—Epistaxis—Capecitabine—esophageal cancer	0.00171	0.00243	CcSEcCtD
Tiagabine—Irritability—Methotrexate—esophageal cancer	0.00167	0.00237	CcSEcCtD
Tiagabine—Mood swings—Methotrexate—esophageal cancer	0.00166	0.00235	CcSEcCtD
Tiagabine—Ataxia—Methotrexate—esophageal cancer	0.00165	0.00234	CcSEcCtD
Tiagabine—Myalgia—Cisplatin—esophageal cancer	0.00164	0.00232	CcSEcCtD
Tiagabine—Haemoglobin—Capecitabine—esophageal cancer	0.00164	0.00232	CcSEcCtD
Tiagabine—Rhinitis—Capecitabine—esophageal cancer	0.00163	0.00231	CcSEcCtD
Tiagabine—Anxiety—Cisplatin—esophageal cancer	0.00163	0.00231	CcSEcCtD
Tiagabine—Haemorrhage—Capecitabine—esophageal cancer	0.00163	0.00231	CcSEcCtD
Tiagabine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00162	0.0023	CcSEcCtD
Tiagabine—Liver function test abnormal—Methotrexate—esophageal cancer	0.00162	0.00229	CcSEcCtD
Tiagabine—Discomfort—Cisplatin—esophageal cancer	0.00162	0.00229	CcSEcCtD
Tiagabine—Pharyngitis—Capecitabine—esophageal cancer	0.00162	0.00229	CcSEcCtD
Tiagabine—Oedema peripheral—Capecitabine—esophageal cancer	0.0016	0.00227	CcSEcCtD
Tiagabine—Oedema—Cisplatin—esophageal cancer	0.00157	0.00223	CcSEcCtD
Tiagabine—Visual impairment—Capecitabine—esophageal cancer	0.00157	0.00223	CcSEcCtD
Tiagabine—Infection—Cisplatin—esophageal cancer	0.00156	0.00221	CcSEcCtD
Tiagabine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00154	0.00218	CcSEcCtD
Tiagabine—Tachycardia—Cisplatin—esophageal cancer	0.00153	0.00217	CcSEcCtD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00152	0.00515	CbGpPWpGaD
Tiagabine—Tinnitus—Capecitabine—esophageal cancer	0.00152	0.00215	CcSEcCtD
Tiagabine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00152	0.00215	CcSEcCtD
Tiagabine—Asthma—Methotrexate—esophageal cancer	0.00151	0.00215	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00151	0.00512	CbGpPWpGaD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.0015	0.00508	CbGpPWpGaD
Tiagabine—Anorexia—Cisplatin—esophageal cancer	0.00149	0.00212	CcSEcCtD
Tiagabine—Hypotension—Cisplatin—esophageal cancer	0.00147	0.00208	CcSEcCtD
Tiagabine—Chills—Capecitabine—esophageal cancer	0.00146	0.00207	CcSEcCtD
Tiagabine—Alopecia—Capecitabine—esophageal cancer	0.00144	0.00204	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00143	0.00203	CcSEcCtD
Tiagabine—CYP3A4—Tryptophan metabolism—ALDH2—esophageal cancer	0.00143	0.00483	CbGpPWpGaD
Tiagabine—Dysuria—Methotrexate—esophageal cancer	0.00142	0.00201	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.00141	0.00477	CbGpPWpGaD
Tiagabine—Paraesthesia—Cisplatin—esophageal cancer	0.00141	0.002	CcSEcCtD
Tiagabine—Dyspnoea—Cisplatin—esophageal cancer	0.0014	0.00198	CcSEcCtD
Tiagabine—Flatulence—Capecitabine—esophageal cancer	0.0014	0.00198	CcSEcCtD
Tiagabine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00139	0.00198	CcSEcCtD
Tiagabine—Dysgeusia—Capecitabine—esophageal cancer	0.00139	0.00197	CcSEcCtD
Tiagabine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00138	0.00196	CcSEcCtD
Tiagabine—Back pain—Capecitabine—esophageal cancer	0.00137	0.00194	CcSEcCtD
Tiagabine—Decreased appetite—Cisplatin—esophageal cancer	0.00136	0.00193	CcSEcCtD
Tiagabine—Muscle spasms—Capecitabine—esophageal cancer	0.00136	0.00193	CcSEcCtD
Tiagabine—Pneumonia—Methotrexate—esophageal cancer	0.00136	0.00193	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00135	0.00458	CbGpPWpGaD
Tiagabine—Depression—Methotrexate—esophageal cancer	0.00135	0.00191	CcSEcCtD
Tiagabine—Pain—Cisplatin—esophageal cancer	0.00134	0.0019	CcSEcCtD
Tiagabine—Tremor—Capecitabine—esophageal cancer	0.00133	0.00188	CcSEcCtD
Tiagabine—Renal failure—Methotrexate—esophageal cancer	0.00133	0.00188	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00133	0.00449	CbGpPWpGaD
Tiagabine—Stomatitis—Methotrexate—esophageal cancer	0.00132	0.00187	CcSEcCtD
Tiagabine—Ill-defined disorder—Capecitabine—esophageal cancer	0.00131	0.00186	CcSEcCtD
Tiagabine—Conjunctivitis—Methotrexate—esophageal cancer	0.00131	0.00186	CcSEcCtD
Tiagabine—Anaemia—Capecitabine—esophageal cancer	0.00131	0.00186	CcSEcCtD
Tiagabine—Sweating—Methotrexate—esophageal cancer	0.00129	0.00184	CcSEcCtD
Tiagabine—Feeling abnormal—Cisplatin—esophageal cancer	0.00129	0.00183	CcSEcCtD
Tiagabine—Haematuria—Methotrexate—esophageal cancer	0.00129	0.00183	CcSEcCtD
Tiagabine—Malaise—Capecitabine—esophageal cancer	0.00128	0.00181	CcSEcCtD
Tiagabine—Epistaxis—Methotrexate—esophageal cancer	0.00127	0.00181	CcSEcCtD
Tiagabine—Vertigo—Capecitabine—esophageal cancer	0.00127	0.00181	CcSEcCtD
Tiagabine—Syncope—Capecitabine—esophageal cancer	0.00127	0.0018	CcSEcCtD
Tiagabine—Leukopenia—Capecitabine—esophageal cancer	0.00127	0.0018	CcSEcCtD
Tiagabine—Palpitations—Capecitabine—esophageal cancer	0.00125	0.00178	CcSEcCtD
Tiagabine—Loss of consciousness—Capecitabine—esophageal cancer	0.00125	0.00177	CcSEcCtD
Tiagabine—Body temperature increased—Cisplatin—esophageal cancer	0.00124	0.00176	CcSEcCtD
Tiagabine—Cough—Capecitabine—esophageal cancer	0.00124	0.00175	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00123	0.00418	CbGpPWpGaD
Tiagabine—Hypertension—Capecitabine—esophageal cancer	0.00122	0.00174	CcSEcCtD
Tiagabine—Haemoglobin—Methotrexate—esophageal cancer	0.00122	0.00173	CcSEcCtD
Tiagabine—Haemorrhage—Methotrexate—esophageal cancer	0.00121	0.00172	CcSEcCtD
Tiagabine—Arthralgia—Capecitabine—esophageal cancer	0.00121	0.00171	CcSEcCtD
Tiagabine—Chest pain—Capecitabine—esophageal cancer	0.00121	0.00171	CcSEcCtD
Tiagabine—Myalgia—Capecitabine—esophageal cancer	0.00121	0.00171	CcSEcCtD
Tiagabine—Pharyngitis—Methotrexate—esophageal cancer	0.0012	0.00171	CcSEcCtD
Tiagabine—Anxiety—Capecitabine—esophageal cancer	0.0012	0.00171	CcSEcCtD
Tiagabine—Discomfort—Capecitabine—esophageal cancer	0.00119	0.00169	CcSEcCtD
Tiagabine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00119	0.00403	CbGpPWpGaD
Tiagabine—Dry mouth—Capecitabine—esophageal cancer	0.00118	0.00167	CcSEcCtD
Tiagabine—Visual impairment—Methotrexate—esophageal cancer	0.00117	0.00166	CcSEcCtD
Tiagabine—Confusional state—Capecitabine—esophageal cancer	0.00117	0.00165	CcSEcCtD
Tiagabine—Oedema—Capecitabine—esophageal cancer	0.00116	0.00164	CcSEcCtD
Tiagabine—Hypersensitivity—Cisplatin—esophageal cancer	0.00116	0.00164	CcSEcCtD
Tiagabine—Infection—Capecitabine—esophageal cancer	0.00115	0.00163	CcSEcCtD
Tiagabine—Shock—Capecitabine—esophageal cancer	0.00114	0.00161	CcSEcCtD
Tiagabine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.00113	0.00384	CbGpPWpGaD
Tiagabine—Thrombocytopenia—Capecitabine—esophageal cancer	0.00113	0.00161	CcSEcCtD
Tiagabine—Tinnitus—Methotrexate—esophageal cancer	0.00113	0.0016	CcSEcCtD
Tiagabine—Tachycardia—Capecitabine—esophageal cancer	0.00113	0.0016	CcSEcCtD
Tiagabine—Asthenia—Cisplatin—esophageal cancer	0.00113	0.0016	CcSEcCtD
Tiagabine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00112	0.00159	CcSEcCtD
Tiagabine—Anorexia—Capecitabine—esophageal cancer	0.0011	0.00156	CcSEcCtD
Tiagabine—Chills—Methotrexate—esophageal cancer	0.00109	0.00154	CcSEcCtD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00108	0.00367	CbGpPWpGaD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP1B1—esophageal cancer	0.00108	0.00366	CbGpPWpGaD
Tiagabine—Hypotension—Capecitabine—esophageal cancer	0.00108	0.00153	CcSEcCtD
Tiagabine—Diarrhoea—Cisplatin—esophageal cancer	0.00107	0.00152	CcSEcCtD
Tiagabine—Alopecia—Methotrexate—esophageal cancer	0.00107	0.00152	CcSEcCtD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00107	0.00362	CbGpPWpGaD
Tiagabine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00105	0.00149	CcSEcCtD
Tiagabine—Insomnia—Capecitabine—esophageal cancer	0.00105	0.00148	CcSEcCtD
Tiagabine—Paraesthesia—Capecitabine—esophageal cancer	0.00104	0.00147	CcSEcCtD
Tiagabine—Dysgeusia—Methotrexate—esophageal cancer	0.00103	0.00147	CcSEcCtD
Tiagabine—Dyspnoea—Capecitabine—esophageal cancer	0.00103	0.00146	CcSEcCtD
Tiagabine—Back pain—Methotrexate—esophageal cancer	0.00102	0.00145	CcSEcCtD
Tiagabine—Dyspepsia—Capecitabine—esophageal cancer	0.00102	0.00144	CcSEcCtD
Tiagabine—CYP3A4—Tryptophan metabolism—CYP19A1—esophageal cancer	0.00102	0.00344	CbGpPWpGaD
Tiagabine—Decreased appetite—Capecitabine—esophageal cancer	0.001	0.00143	CcSEcCtD
Tiagabine—Vomiting—Cisplatin—esophageal cancer	0.000997	0.00141	CcSEcCtD
Tiagabine—Fatigue—Capecitabine—esophageal cancer	0.000997	0.00141	CcSEcCtD
Tiagabine—Rash—Cisplatin—esophageal cancer	0.000989	0.0014	CcSEcCtD
Tiagabine—Constipation—Capecitabine—esophageal cancer	0.000989	0.0014	CcSEcCtD
Tiagabine—Pain—Capecitabine—esophageal cancer	0.000989	0.0014	CcSEcCtD
Tiagabine—Dermatitis—Cisplatin—esophageal cancer	0.000988	0.0014	CcSEcCtD
Tiagabine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000978	0.00139	CcSEcCtD
Tiagabine—Anaemia—Methotrexate—esophageal cancer	0.000975	0.00138	CcSEcCtD
Tiagabine—Feeling abnormal—Capecitabine—esophageal cancer	0.000953	0.00135	CcSEcCtD
Tiagabine—Malaise—Methotrexate—esophageal cancer	0.000951	0.00135	CcSEcCtD
Tiagabine—Vertigo—Methotrexate—esophageal cancer	0.000947	0.00134	CcSEcCtD
Tiagabine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000945	0.00134	CcSEcCtD
Tiagabine—Leukopenia—Methotrexate—esophageal cancer	0.000944	0.00134	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000934	0.00317	CbGpPWpGaD
Tiagabine—Nausea—Cisplatin—esophageal cancer	0.000932	0.00132	CcSEcCtD
Tiagabine—Cough—Methotrexate—esophageal cancer	0.00092	0.00131	CcSEcCtD
Tiagabine—Urticaria—Capecitabine—esophageal cancer	0.000918	0.0013	CcSEcCtD
Tiagabine—Abdominal pain—Capecitabine—esophageal cancer	0.000914	0.0013	CcSEcCtD
Tiagabine—Body temperature increased—Capecitabine—esophageal cancer	0.000914	0.0013	CcSEcCtD
Tiagabine—SLC6A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000904	0.00306	CbGpPWpGaD
Tiagabine—Chest pain—Methotrexate—esophageal cancer	0.000898	0.00127	CcSEcCtD
Tiagabine—Myalgia—Methotrexate—esophageal cancer	0.000898	0.00127	CcSEcCtD
Tiagabine—Arthralgia—Methotrexate—esophageal cancer	0.000898	0.00127	CcSEcCtD
Tiagabine—Discomfort—Methotrexate—esophageal cancer	0.000887	0.00126	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000879	0.00298	CbGpPWpGaD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000874	0.00296	CbGpPWpGaD
Tiagabine—Confusional state—Methotrexate—esophageal cancer	0.000868	0.00123	CcSEcCtD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000862	0.00292	CbGpPWpGaD
Tiagabine—Infection—Methotrexate—esophageal cancer	0.000855	0.00121	CcSEcCtD
Tiagabine—Hypersensitivity—Capecitabine—esophageal cancer	0.000852	0.00121	CcSEcCtD
Tiagabine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000843	0.0012	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000833	0.00282	CbGpPWpGaD
Tiagabine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000832	0.00118	CcSEcCtD
Tiagabine—Asthenia—Capecitabine—esophageal cancer	0.000829	0.00118	CcSEcCtD
Tiagabine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000821	0.00278	CbGpPWpGaD
Tiagabine—Anorexia—Methotrexate—esophageal cancer	0.00082	0.00116	CcSEcCtD
Tiagabine—Pruritus—Capecitabine—esophageal cancer	0.000818	0.00116	CcSEcCtD
Tiagabine—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000811	0.00275	CbGpPWpGaD
Tiagabine—Hypotension—Methotrexate—esophageal cancer	0.000804	0.00114	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—ADH7—esophageal cancer	0.000803	0.00272	CbGpPWpGaD
Tiagabine—Diarrhoea—Capecitabine—esophageal cancer	0.000791	0.00112	CcSEcCtD
Tiagabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000784	0.00111	CcSEcCtD
Tiagabine—Insomnia—Methotrexate—esophageal cancer	0.000778	0.0011	CcSEcCtD
Tiagabine—Paraesthesia—Methotrexate—esophageal cancer	0.000773	0.0011	CcSEcCtD
Tiagabine—Dyspnoea—Methotrexate—esophageal cancer	0.000767	0.00109	CcSEcCtD
Tiagabine—Somnolence—Methotrexate—esophageal cancer	0.000765	0.00109	CcSEcCtD
Tiagabine—Dizziness—Capecitabine—esophageal cancer	0.000764	0.00108	CcSEcCtD
Tiagabine—Dyspepsia—Methotrexate—esophageal cancer	0.000758	0.00107	CcSEcCtD
Tiagabine—Decreased appetite—Methotrexate—esophageal cancer	0.000748	0.00106	CcSEcCtD
Tiagabine—Fatigue—Methotrexate—esophageal cancer	0.000742	0.00105	CcSEcCtD
Tiagabine—Pain—Methotrexate—esophageal cancer	0.000736	0.00104	CcSEcCtD
Tiagabine—Vomiting—Capecitabine—esophageal cancer	0.000735	0.00104	CcSEcCtD
Tiagabine—Rash—Capecitabine—esophageal cancer	0.000729	0.00103	CcSEcCtD
Tiagabine—Dermatitis—Capecitabine—esophageal cancer	0.000728	0.00103	CcSEcCtD
Tiagabine—Headache—Capecitabine—esophageal cancer	0.000724	0.00103	CcSEcCtD
Tiagabine—Feeling abnormal—Methotrexate—esophageal cancer	0.000709	0.00101	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000708	0.0024	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—ADH1B—esophageal cancer	0.000704	0.00239	CbGpPWpGaD
Tiagabine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000704	0.000999	CcSEcCtD
Tiagabine—Nausea—Capecitabine—esophageal cancer	0.000687	0.000974	CcSEcCtD
Tiagabine—Urticaria—Methotrexate—esophageal cancer	0.000684	0.00097	CcSEcCtD
Tiagabine—Body temperature increased—Methotrexate—esophageal cancer	0.00068	0.000965	CcSEcCtD
Tiagabine—Abdominal pain—Methotrexate—esophageal cancer	0.00068	0.000965	CcSEcCtD
Tiagabine—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000666	0.00226	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP26A1—esophageal cancer	0.000655	0.00222	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000646	0.00219	CbGpPWpGaD
Tiagabine—Hypersensitivity—Methotrexate—esophageal cancer	0.000634	0.0009	CcSEcCtD
Tiagabine—Asthenia—Methotrexate—esophageal cancer	0.000617	0.000876	CcSEcCtD
Tiagabine—Pruritus—Methotrexate—esophageal cancer	0.000609	0.000864	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—GSTO1—esophageal cancer	0.000609	0.00206	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—GSTO1—esophageal cancer	0.000601	0.00203	CbGpPWpGaD
Tiagabine—Diarrhoea—Methotrexate—esophageal cancer	0.000589	0.000835	CcSEcCtD
Tiagabine—Dizziness—Methotrexate—esophageal cancer	0.000569	0.000807	CcSEcCtD
Tiagabine—Vomiting—Methotrexate—esophageal cancer	0.000547	0.000776	CcSEcCtD
Tiagabine—Rash—Methotrexate—esophageal cancer	0.000543	0.00077	CcSEcCtD
Tiagabine—Dermatitis—Methotrexate—esophageal cancer	0.000542	0.000769	CcSEcCtD
Tiagabine—Headache—Methotrexate—esophageal cancer	0.000539	0.000765	CcSEcCtD
Tiagabine—Nausea—Methotrexate—esophageal cancer	0.000511	0.000725	CcSEcCtD
Tiagabine—CYP3A4—Biological oxidations—ALDH2—esophageal cancer	0.000496	0.00168	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—GSTT1—esophageal cancer	0.000472	0.0016	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP2A6—esophageal cancer	0.000467	0.00158	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—PTGS1—esophageal cancer	0.000442	0.0015	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP1B1—esophageal cancer	0.000376	0.00127	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000371	0.00126	CbGpPWpGaD
Tiagabine—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000354	0.0012	CbGpPWpGaD
Tiagabine—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000349	0.00118	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—BLVRB—esophageal cancer	0.00019	0.000644	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC52A3—esophageal cancer	0.00019	0.000644	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CA1—esophageal cancer	0.000162	0.000547	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	0.000162	0.000547	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CA2—esophageal cancer	0.000148	0.000501	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PLCE1—esophageal cancer	0.000137	0.000465	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ADH7—esophageal cancer	0.000137	0.000465	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ADH1B—esophageal cancer	0.00012	0.000408	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TYMP—esophageal cancer	0.000115	0.00039	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	0.000112	0.000379	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ALOX15—esophageal cancer	0.000109	0.00037	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—TPI1—esophageal cancer	0.000104	0.000353	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTO1—esophageal cancer	0.000104	0.000353	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ALDOB—esophageal cancer	9.98e-05	0.000338	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GAPDH—esophageal cancer	9.61e-05	0.000326	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CRABP1—esophageal cancer	9.52e-05	0.000323	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GNG7—esophageal cancer	9.06e-05	0.000307	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ALDH2—esophageal cancer	8.49e-05	0.000288	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—GSTT1—esophageal cancer	8.07e-05	0.000273	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	7.98e-05	0.00027	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTGS1—esophageal cancer	7.57e-05	0.000256	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ENO1—esophageal cancer	7.57e-05	0.000256	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PSME2—esophageal cancer	7.46e-05	0.000253	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PSME1—esophageal cancer	7.46e-05	0.000253	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	6.43e-05	0.000218	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	6.05e-05	0.000205	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—HMOX1—esophageal cancer	5.52e-05	0.000187	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—ABCB1—esophageal cancer	5.3e-05	0.000179	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—CREBBP—esophageal cancer	3.54e-05	0.00012	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—NOS3—esophageal cancer	3.17e-05	0.000107	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PTGS2—esophageal cancer	2.9e-05	9.82e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—EP300—esophageal cancer	2.41e-05	8.17e-05	CbGpPWpGaD
Tiagabine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.78e-05	6.04e-05	CbGpPWpGaD
